Last reviewed · How we verify
CERC-002
At a glance
| Generic name | CERC-002 |
|---|---|
| Also known as | AEVI-002 and MDGN-002 |
| Sponsor | Aevi Genomic Medicine, LLC, a Cerecor company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma. (PHASE2)
- Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CERC-002 CI brief — competitive landscape report
- CERC-002 updates RSS · CI watch RSS
- Aevi Genomic Medicine, LLC, a Cerecor company portfolio CI